Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Rhea-AI Summary

Aditxt (NASDAQ: ADTX) has announced a stakeholder update and Q&A session scheduled for Friday, October 11, 2024, at 11:30 AM EDT. CEO Amro Albanna will lead the session, covering:

• Company overview and updates on Evofem and Appili transactions
• Current programs in immune and precision health
• Year-end roadmap for 2024
• Q&A segment addressing pre-submitted questions

Aditxt operates two programs focused on immune health and precision health, with plans to introduce two additional programs in public health and women's health. The company has entered into agreements with Appili Therapeutics and Evofem Biosciences for these new programs. Aditxt's innovation platform aims to accelerate promising health innovations through collaboration with research institutions, industry partners, and shareholders.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (“Aditxt” “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM EDT. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company’s latest developments and will address pre-submitted questions.

This week’s session will cover:

• Aditxt Overview and Transaction Updates: An update on the Company’s current position and progress regarding the Evofem and Appili transactions.
• Overview of Aditxt’s Current Programs: Updates on Aditxt’s two ongoing programs in immune and precision health.
• Year-End Roadmap: Insights into Aditxt’s plans and goals for the remainder of 2024.
• Q&A Segment: Amro Albanna will respond to questions submitted in advance.

Stakeholders can submit their questions for the upcoming sessions by Thursday, October 10, 2024 at 5:00 PM EDT to engagement@aditxt.com. To register for the session, please visit this link.

“Our stakeholders are key to our success,” said Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt. “It is critical for us to communicate our status and plans effectively and continuously. Sessions like this allow us to keep our stakeholders informed and engaged, providing them with a clear understanding of our progress, challenges, and the potential of our programs and strategic initiatives.”

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For the latter two programs, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), which focuses on women’s health. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each transaction with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

About Aditxt, Inc.

Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

For more information, www.aditxt.com.

Follow us on:

LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241009619012/en/

Media Relations Contact:

Mary O’ Brien

mobrien@aditxt.com

(516) 753-9933

Source: Aditxt, Inc.

FAQ

When is Aditxt (ADTX) hosting its stakeholder update and Q&A session?

Aditxt (ADTX) is hosting its stakeholder update and Q&A session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time.

What topics will be covered in Aditxt's (ADTX) upcoming stakeholder update?

The update will cover Aditxt's overview and transaction updates, current programs in immune and precision health, year-end roadmap for 2024, and a Q&A segment addressing pre-submitted questions.

What new programs is Aditxt (ADTX) planning to introduce?

Aditxt (ADTX) is planning to introduce two additional programs dedicated to public health and women's health, in addition to its current programs focused on immune health and precision health.

Which companies has Aditxt (ADTX) entered into agreements with for its new programs?

Aditxt (ADTX) has entered into an Arrangement Agreement with Appili Therapeutics (TSX: APLI; OTCPink: APLIF) for infectious diseases and a Merger Agreement with Evofem Biosciences (OTCQB: EVFM) for women's health.

How can stakeholders submit questions for Aditxt's (ADTX) Q&A session?

Stakeholders can submit their questions for Aditxt's (ADTX) Q&A session by Thursday, October 10, 2024, at 5:00 PM EDT to engagement@aditxt.com.